[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uroepithelial-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uroepithelial-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100581542","phase-2-trop2-targeted-immunopet-imaging-of-solid-tumors-100581542",false,"NCT06851663","Trop2-targeted immunoPET Imaging of Solid Tumors","Inclusion Criteria:\n\n* Aged 18-75 year-old and of either sex\n* Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","ALL","18 Years","75 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Solid Tumor","Solid Carcinoma","Uroepithelial Carcinoma","Bladder Cancer","Prostate Cancer","Lung Cancer","Nasopharyngeal Cancer","Liver Cancer","Cholangiocarcinoma","Ovarian Cancer","Cervical Cancer","Endometrial Cancer","Thyroid Cancer","Head and Neck Cancer",[42,43,27],"Trophoblast cell surface antigen 2 (Trop2)","ImmunoPET","RECRUITING","2026-05-27",{"date":47,"type":48},"2026-05-29","ACTUAL",{"date":50,"type":48},"2024-12-23",{"date":52,"type":20},"2027-12",{"name":54,"class":55},"RenJi Hospital","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":64,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100567096","current-status-of-diagnosis-and-treatment-of-uroepithelial-carcinoma-100567096","NCT06663735","Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma","A Cross-sectional Study Describing the Current Status of Diagnosis and Treatment of Uroepithelial Cancer in Hospitals of Different Grades in Henan Province","Inclusion Criteria:\n\n* Adults ≥18 years of age (at enrollment)\n* Histologically confirmed uroepithelial carcinoma\n* Patients with newly diagnosed or completed radical uroepithelial carcinoma in the early stages of uroepithelial cancer\u002Fadvanced unresectable or with distant metastases of urothelial carcinoma\n* Complete medical history information\n\nExclusion Criteria:\n\n* Incomplete medical history and medical records",{"count":19,"type":20},"400 Days","OBSERVATIONAL","A cross-sectional study describing the current status of diagnosis and treatment of uroepithelial cancer in hospitals of different grades in Henan Province",[29],[70,71,72],"Henan province","uroepithelial cancer","treatment","NOT_YET_RECRUITING","2024-10-27",{"date":76,"type":48},"2024-10-29",{"date":78,"type":20},"2024-10-30",{"date":80,"type":20},"2025-07-31",{"name":82,"class":55},"The First Affiliated Hospital of Xinxiang Medical College",11]